<DOC>
	<DOCNO>NCT01141257</DOCNO>
	<brief_summary>The purpose study determine Angiocal® ( PRS-050-PEG40 ) safe well tolerate injected vein patient solid tumor . Other purpose study investigate body patient react Angiocal® , blood level Angiocal® develop injection tumor respond injection Angiocal® .</brief_summary>
	<brief_title>Study Angiocal® Patients With Solid Tumors , Investigating Safety , Tolerability , Blood Concentration Study Drug</brief_title>
	<detailed_description>This phase I , open-label , dose escalation study Angiocal® patient solid tumor use group sequential adaptive treatment assignment . Patients allocate different dose level small cohort receive one single dose application Day 1 , follow repeated dosing period . The primary objective study evaluate safety tolerability Angiocal® administer intravenously patient solid tumor . The secondary objective study characterization pharmacodynamic response , evaluation pharmacokinetic profile Angiocal® , observation tumor response .</detailed_description>
	<criteria>Males female advance , recurrent metastatic cancer , refractory standard therapy ; Age ≥18 year ; Signed informed consent form ability understand study procedure . Concomitant anticancer therapy , include radiation ; Current previous ( within 30 day first study dose ) treatment another investigational drug participation another clinical study ; Chronic daily treatment aspirin ( &gt; 325 mg/day ) clopidogrel ( &gt; 75 mg/day ) ; Chronic daily treatment corticosteroid , exception inhale steroid ; Inadequate bone marrow function ; Inadequate liver function ; Inadequate renal function ; Patients receive anticoagulant medication International Normalized Ratio ( INR ) &gt; 1.5 activate partial thromboplastin time ( aPTT ) &gt; 1.5 x ULN within 7 day prior first study treatment ; Patients lymphomas ; Evidence spinal cord compression brain metastasis ; Other malignancy diagnose within previous 5 year ; Pregnant lactating female . ; All patient use highly effective method birth control ; Major surgical procedure ( include open biopsy ) within 28 day prior first study treatment , anticipation need major surgery course study treatment ; Minor surgical procedure , within 24 hour prior first study treatment ; History evidence inherit bleed diathesis coagulopathy risk bleeding ; Uncontrolled hypertension clinically significant ( i.e . active ) cardiovascular disease ; History abdominal fistula , grade 4 bowel obstruction gastrointestinal perforation , intraabdominal abscess within 6 month enrollment ; Lung carcinoma squamous cell histology histology close proximity major vessel ; Serious nonhealing wound , peptic ulcer bone fracture ; Known hypersensitivity study medication excipients ; Evidence medical condition may interfere plan treatment , affect patient compliance place patient high risk treatmentrelated complication ; Previous enrollment study ; Known hepatitis B C HIV infection ; Employees sponsor patient employee relative investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Angiocal® ; PRS-050-PEG40 ; Solid tumor ; Phase I</keyword>
</DOC>